Bevacizumab is a monoclonal antibody against VEGF, and by inhibiting VEGF, bevacizumab inhibits angiogenesis. This inhibition of angiogenesis makes bevacizumab useful for treating solid tumors--since solid tumors need a blood supply to grow. Bevacizumab is also useful for treating wet age-related macular degeneration, which is caused by abnormal development of blood vessels in the eye. Patients taking bevacizumab are at risk for hemorrhage, impaired wound healing, and blood clots.

Key Points

  • Bevacizumab
    • Mechanism
      • Monoclonal antibody against VEGF
        • → inhibits angiogenesis
    • Clinical use
      • Solid tumors
        • Colorectal cancer, renal cell carcinoma
      • Wet age-related macular degeneration
    • Adverse Effects
      • Hemorrhage
      • Blood clots
      • Impaired wound healing